INS and Insulin resistance: Recently, an open-label clinical trial of atorvastatin 40 mg daily in 71 adults without known atherosclerotic cardiovascular disease or type 2 diabetes at baseline investigated the effects on insulin resistance as assessed by steady-state plasma glucose during the insulin suppression test during the graded-glucose infusion test after 10 weeks[19].